LinkedIn IconTwitter Icon

27-29 November 2018
Berlin, Germany

Day One
Wednesday 28 November

Day Two
Thursday 29 November

08.30
Registration and Networking

08.50
Chairs Opening Remarks

  • Jannie Borst Head, Division of Tumor Biology and Immunology, Netherlands Cancer Institute

Personalising Immunotherapy Through Innovative Biomarker Approaches

09.00
Developing a Personalized Immune Monitoring Program: Applications to Personalised Cancer Vaccine (PCV) Therapeutics

09.30
Checkpoint Inhibitor Keytruda® as a Therapeutic Strategy in Oncology

  • Christian Hosius Regional Clinical Director European Clinical Development, Oncology, Merck Sharpe & Dohme

10.00
Panel Discussion: Investigating Biomarkers to Predict Responses to Immunotherapy: Which Factors in the Biological Profile of the Patient Should We Assess?

10.45
Morning Refreshments & Networking

Cancer Immunity Cycle Stages 4-7 Migration, Infiltration & Cancer Cell Killing

11.15
Enticing Cytotoxic T Cells to Attack Cancer: The Importance of CD4 T Cell Help

  • Jannie Borst Head, Division of Tumor Biology and Immunology, Netherlands Cancer Institute

11.45
Discovery & Development of AB154, a Novel Antibody Targeting TIGIT

  • Tim Sullivan Vice President, Business Development, Vice President, Business Development

12.15
Lunch & Networking

Unleashing the Potential of Innate & Adaptive Anti-Tumour Immune Responses

13.15
Enhancing Anti-Tumour Activity by Targeting the Tumour Microenvironment

  • Laura Helming Director, Scientific Site Head, Immuno-Oncology, Merck KGaA

13.45
Next Generation Immunotherapies: Targeting Innate Lymphocytes and Tumour Microenvironment

  • Mathieu Blery Senior Director, Translational Immunology, Innate Pharma

14.15
Gaining Insights into the Development of CD47-Targeted Bispecific Antibodies

  • Walter Ferlin Head of Exploratory Science & Translational Medicine, NovImmune

14.45
Afternoon Refreshments & Networking

Investigating Innovative Therapeutic Constructs to Address Immuno-Oncology Targets More Effectively

15.15
Fibroblast Activation Protein (FAP)-Selective Delivery of CD40 Agonistic DARPin® Protein for Tumour-Localized Immune Activation

  • Nicolo Rigamonti Biology Lead & Project Leader, Cancer Immunology, Molecular Partners

15.45
Panel Discussion: Contrasting Therapeutic Modalities in Immuno- Oncology

  • Marlon Hinner Group Leader, In Vitro Display, Roche
  • Walter Ferlin Head of Exploratory Science & Translational Medicine, NovImmune
  • Nicolo Rigamonti Biology Lead & Project Leader, Cancer Immunology, Molecular Partners

16.15
Chair’s Closing Remarks

  • Jannie Borst Head, Division of Tumor Biology and Immunology, Netherlands Cancer Institute

16.30
Close of Conference